Cellon debuts sterile single-use containers
The range is ideal for use in the handling and storage of biologicals
Called PharmaTainer, the line of products are a range of low particulate, single use bottles and carboys for the storage/transport of bulk vaccines, biopharmaceuticals, culture media and other biotech materials.
The plastic containers are injection blow moulded in an ISO Class 5 (Class100) environment and radiation sterilised. These rigid ultra-clean containers are available in sizes from 125ml to 20L. They are manufactured from resins approved for medical applications in PET or polycarbonate with HDPE closures.
PharmaTainer packaging features three inner layers of poly wrapping to facilitate delivery into cleanroom areas. The inner most layer is vacuum-sealed providing tamper evidence and assurance of an intact sterility barrier.
The range of products feature traceability down to the individual container. Each bottle/carboy is printed with a unique serial number, batch number, expiration date and a machine-readable data matrix. The machine-readable serial number can be readily integrated with the user’s inventory management system.
All PharmaTainer products are produced in a new, moulding facility, dedicated solely to production of sterile, single-use products for biotechnology industries.
European customers may get further information at www.cellon.lu or by email sales@cellon.lu. The products are distributed by Biofluid Focus in North American (www.biofluidfocus.com).
You may also like
Trending Articles
Upcoming event
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
Semaglutide patent cliff: pharma industry braces for impact
With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities
The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258
The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists